Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in
inflammatory bowel diseases to maximize benefit and to reach more stringent, objective end …

Abstract Model-informed precision dosing (MIPD) stands as a significant development in
personalized medicine to tailor drug dosing to individual patient characteristics. MIPD moves …

Crohn's disease [CD] is a chronic inflammatory bowel disease [IBD] that can result in
progressive bowel damage and disability. 1 CD can affect individuals of any age, from …

Background & aims Excessive inflammatory responses and oxidative stress are considered
the main characteristics of inflammatory bowel disease (IBD). Endogenous hydrogen sulfide …

Background & Aims Proactive therapeutic drug monitoring (TDM) has been proposed to
improve outcomes in patients with inflammatory bowel disease (IBD) treated with tumor …

Inflammatory bowel diseases (IBD) encompass two main entities including ulcerative colitis
and Crohn's disease. Although having a common global pathophysiological mechanism …

The intestinal epithelial repair after injury is coordinated by intestinal stem cells (ISCs).
Fucosylation catalyzed by fucosyltransferase 2 (FUT2) of the intestinal epithelium is …

Emerging biologics and small-molecule drugs have changed the clinical status quo of
inflammatory bowel disease (IBD). However, current treatments remain at a standstill in …

Background There are a plethora of therapeutic options for the management of inflammatory
bowel disease (IBD). Despite this, clinical outcomes with standard dosing often fall short of …

Abstract The PD-1/PD-L1 pathway in mucosal immunity is currently actively explored and
considered as a target for inflammatory bowel disease (IBD) treatment. However, systemic …